What is Abionic?
Founded in 2010, Abionic has established itself as a leader in the rapid diagnostic sector, earning recognition as the Swiss MedTech of the Year in 2023. The company's core value proposition centers on the abioSCOPE, a sophisticated platform capable of delivering laboratory-grade diagnostic results from a single drop of blood in mere minutes. This technology is specifically engineered to integrate into high-pressure environments such as emergency rooms and intensive care units, where rapid clinical decision-making is critical for patient survival.
By focusing on conditions like sepsis, Abionic addresses a significant unmet need in clinical diagnostics. Their approach minimizes the time-to-result, thereby optimizing hospital workflows and improving patient outcomes. The company serves a diverse range of healthcare institutions, positioning itself as an essential partner for providers seeking to modernize their diagnostic infrastructure.
How much funding has Abionic raised?
Abionic has raised a total of $7.7M across 2 funding rounds:
Series A
$3.7M
Series B
$4M
Series A (2012): $3.7M, investors not publicly disclosed
Series B (2014): $4M led by BlueOcean Ventures SA and Drexel Morgan & Co
Key Investors in Abionic
BlueOcean Ventures SA
BlueOcean Ventures is an investment company focused on early-stage medical device and life science companies, targeting untapped markets.
Drexel Morgan & Co
Drexel Morgan Capital Advisers Inc is a company that operates in the Investment Banking industry, providing strategic financial advisory services.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Abionic?
With the recent strategic investment, Abionic is poised to accelerate its commercialization efforts and deepen its penetration into international markets. The company's roadmap likely involves expanding the diagnostic menu of the abioSCOPE platform to cover a broader spectrum of acute conditions, further cementing its role in point-of-care testing. As the firm transitions from a development-focused entity to a scaling enterprise, the focus will shift toward operational excellence and the strengthening of its global distribution network.
Strategic priorities will likely include enhancing the integration of its diagnostic data into existing hospital information systems, ensuring that clinicians have seamless access to actionable insights. By leveraging its recent capital injection, Abionic is set to maintain its competitive edge in the rapidly evolving MedTech landscape, driving innovation that bridges the gap between laboratory precision and bedside efficiency.
